News and Press Releases
Mestag Therapeutics Announces the First Patient Dosed with MST-0312 in the Phase I STARLYS Trial
STARLYS trial to evaluate the potential of MST-0312, a targeted lymphotoxin-beta (LTBR) agonist bispecific antibody, as a novel therapeutic strategy for the treatment of solid tumors Study to evaluate tertiary...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 19, 2026
Suite 15 Science Village, Chesterford Research Park, Little Chesterford, Cambridge, CB10 1XL UK
Immuthera Announces Global Exclusive License from City of Hope for First-in-Class CD6/CTLA-4 CAR-Treg Platform for Autoimmune and Inflammatory Diseases
Global exclusivity for Type 1 Diabetes, Rheumatoid Arthritis, 8 Dermatological Autoimmune diseases, and 13 Neuroinflammatory Autoimmune diseases Six patients with Chronic Graft versus Host Disease treated to-date with a favorable...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: January 12, 2026
Nilo Therapeutics launches with $101 million Series A financing to advance a new class of medicines targeting neural circuits in immune disease and appoints Kim Seth as Chief Executive Officer
Series A led by The Column Group, DCVC Bio, and Lux Capital, with participation from the Gates Foundation and Alexandria Venture Investments 8 October 2025 -- New York, New York...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: October 8, 2025
Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease
RTX001 is the first engineered Regenerative Macrophage Therapy (RMT) to be evaluated in humans with advanced liver fibrosis First patient has successfully cleared safety period with no serious adverse events...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other
Posted: September 3, 2025
Centre for Regenerative Medicine, University of Edinburgh, 5 Little France Drive, Edinburgh, EH16 4UU
Redx presents Phase 1 data supporting RXC008 as a novel and well tolerated drug candidate in development for the potential treatment of fibrostenotic Crohn’s disease
Orally administered pan-ROCK inhibitor demonstrated intestinal tissue exposure and target engagement with minimal plasma concentrations A Phase 2 study is being planned. 6 May 2025 -- Alderley Park, UK --...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 6, 2025
Block 33 Mereside, Alderley Park Alderley Edge Macclesfield SK10 4TG UK
Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025
Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 30, 2025
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations underway to initiate Phase 2b...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 24, 2025
Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025
Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology breakthrough properties for its...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: April 1, 2025
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France
Domain Therapeutics Discloses DT-9046 as a Groundbreaking Oral Drug Candidate for Inflammatory Diseases
DT-9046 is a highly differentiated first-in-class biased negative allosteric modulator of PAR2 with game changing potential across multiple inflammatory diseases Unique mechanism of action with potential to directly impact inflammation,...
Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025
PARC D'INNOVATION 220 Boulevard Gonthier D'Andernach 67400 Strasbourg - Illkirch - France
Bioxodes obtains Orphan Drug Designation for hemorrhagic stroke therapeutic candidate in US and Europe
FDA, EMA grant BIOX-101 ODD status to treat intracerebral hemorrhagic stroke (ICH) ODD status may expedite drug candidate development and approvals BIOX-101 interim Phase 2a data in ICH imminent. 5...
Category: Drug Discovery, Other, Pharmaceutical
Posted: March 5, 2025
GILEAD AND LEO PHARMA ENTER INTO STRATEGIC PARTNERSHIP TO ACCELERATE DEVELOPMENT OF ORAL STAT6 PROGRAM WITHPOTENTIAL IN MULTIPLE INFLAMMATORY DISEASES
11 January 2025 – Foster City, California, US and Ballerup, Denmark – Gilead Sciences, Inc. (Nasdaq: GILD) andLEO Pharmatoday announced a strategic partnership to accelerate the development and commercialization of...
Category: Pharmaceutical
Posted: January 13, 2025
AbbVie’s SKYRIZI® (risankizumab) Accepted by the Scottish Medicines Consortium for Adults with Moderately to Severely Active Ulcerative Colitis
Risankizumab will be available on the NHS in Scotland for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to,...
Category: Clinical Trials, Pharmaceutical
Posted: January 13, 2025
Gilead and Leo Pharma Enter into Strategic Partnership to Accelerate Development of Oral STAT6 Program with Potential in Multiple Inflammatory Diseases
Strategic Partnership Strengthens Gilead’s Inflammation Research Portfolio with the Addition of LEO Pharma’s Preclinical Oral STAT6 Program, Including Targeted Protein Degraders Gilead Will Have Exclusive Global Rights to the STAT6...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 11, 2025
Mage Biologics announces first subject dosed in a phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease
12 June 2024 -- Delaware, US -- Mage Biologics announces it has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 19, 2024
Mage Biologics announces first subject dosed in a Phase 1 trial with MB-001, an orally administered antibody for Inflammatory Bowel Disease
12 June 2024 -- Delaware, US -- Mage Biologics announces it has dosed the first study participant in a first-in-human study of MB-001, a best-in-class orally administered antibody designed for...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024
